CYT NASDAQ
Cyteir Therapeutics, Inc.
1W: +0.0%
1M: -0.3%
3M: -2.9%
1Y: +63.6%
$3.02
Last traded 2024-04-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$108.7M
52W Range1.65-3.19
Volume1,006,884
Avg Volume171,443
Beta0.10
Dividend—
Analyst Ratings
Company Info
CEOMarkus F. Renschler
Employees46
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-18
Websitecyteir.com
128 Spring Street
Lexington, MA 02421
US
Lexington, MA 02421
US
857 285 4140
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Leonard Braden Micha | P-Purchase | 170,589 | $2.95 | 2024-03-20 |
| Leonard Braden Micha | P-Purchase | 113,777 | $3.01 | 2024-03-18 |
| Leonard Braden Micha | 0 | — | 2024-03-15 | |
| Leonard Braden Micha | 0 | — | 2024-03-15 | |
| Gaiero David G | M-Exempt | 2,373 | $1.69 | 2024-03-04 |